Advances in Oral Systemic Treatments for Management of Atopic Dermatitis

After a brief introduction, medical experts review the pathophysiology of atopic dermatitis and explain how JAK inhibitors modulate this inflammatory condition.

Medical experts review the FDA-approved oral JAK inhibitors for atopic dermatitis (abrocitinib, upadacitinib), highlighting differences from conventional therapies, their appeal, and the criteria for recommending them based on disease severity and patient characteristics.

Medical experts discuss the patient screening process for oral JAK inhibitors and identify absolute or relative contraindications.

Medical experts review phase 3 and long-term efficacy and safety data for abrocitinib and upadacitinib in atopic dermatitis and discuss how these data influence treatment decisions and any ongoing safety concerns.

Medical experts discuss long-term data for other systemic agents in atopic dermatitis and how this information informs their treatment decisions.

Medical experts review and comment on the effectiveness of oral JAK inhibitors in providing itch relief for patients with atopic dermatitis.

Medical experts discuss the significance of speed in achieving itch relief when choosing a treatment for atopic dermatitis.

Medical experts evaluate the role of biologics in atopic dermatitis, including their efficacy and safety, and discuss reasons for switching between systemic treatments.

Medical experts discuss the importance of setting treatment expectations and maintaining dialogue with patients about targets and explain how to decide on a new treatment when switching.

Medical experts discuss disease control with abrocitinib or upadacitinib in patients previously taking dupilumab and explain the circumstances under which they would switch a patient to a JAK inhibitor.

Medical experts discuss how often patients with atopic dermatitis request treatment breaks, their monitoring approach during these breaks, and how to educate and counsel patients about treatment breaks and rescue treatments, including identifying suitable candidates.

Medical experts rate dermatologists’ comfort with switching to JAK inhibitors and describe how frequently to switch patients from biologics to JAK inhibitors, including their treatment strategy for this population.

Medical experts review the data on the use of oral JAK inhibitors for maintenance and rescue treatments in atopic dermatitis.

Medical experts share their final thoughts on the future of atopic dermatitis treatment with oral systemic agents.